Ticker brief
PLSE
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
8
authors 14d
4
crowd 14d
+0.30
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-14 · now +0.23 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @zohmbastic | C | -2.94 | 3 | +0.35 |
| @PrismMarketView | C | · | 3 | +0.17 |
| @TradeIdeasLLC | C | · | 1 | +0.00 |
| @PrismDM | A | -2.76 | 1 | +0.25 |
Recent signals8of 8 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-14 | @PrismDM | +0.25 | Pulse Biosciences partnered with Clayman Thyroid Center on commercial use and research for nPulse Vybrance. | · | tweet ↗ |
| 2026-10-14 | @PrismMarketView | +0.20 | Pulse partnered with a treatment center for rollout and research. | · | tweet ↗ |
| 2026-10-13 | @zohmbastic | +0.25 | Attributes PLSE's sustained move to a Duggan filing. | · | tweet ↗ |
| 2026-10-13 | @zohmbastic | +0.40 | Oppenheimer and Mizuho raised PLSE targets while Oppenheimer retained Outperform. | · | tweet ↗ |
| 2026-10-08 | @PrismMarketView | +0.05 | Announces an upcoming symposium presentation on preclinical prototype catheter evaluation. | · | tweet ↗ |
| 2026-10-07 | @PrismMarketView | +0.25 | Pulse Biosciences reached its pivotal study enrollment target of 164 patients. | · | tweet ↗ |
| 2026-10-06 | @TradeIdeasLLC | +0.00 | Daily swing-setup watchlist with price alerts but no stated entry intent. | · | tweet ↗ |
| 2026-10-06 | @zohmbastic | +0.40 | Canaccord raised Pulse Biosciences' price target to $58 from $43 and maintained Buy. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.